newsfilter
← Latest News
GlobeNewswire·

PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics

PETV
  • PetVivo Animal Health, Inc. entered a Vendor Partner Agreement with Veterinary Growth Partners (VGP) to expand market access for its medical devices.
  • VGP serves over 7,300 veterinary members across the United States and will promote PetVivo's flagship products to its network.
  • The agreement provides streamlined access to Spryng with OsteoCushion Technology, an intra-articular injectable device for managing joint pain in dogs, cats, & horses.
  • PrecisePRP, a first-in-class off-the-shelf platelet-rich plasma product, will also be distributed to VGP members for use in dogs & horses without requiring blood draws or centrifugation.
  • Each vial of PrecisePRP contains a consistent dose of 4 billion platelets per vial with less than 1500 white blood cells per microliter.
  • PetVivo CEO John Lai stated the partnership accelerates their mission to improve animal quality of life through advanced science.
  • VGP CEO Rob Sigman noted that PetVivo's products align with their commitment to delivering proven solutions for veterinary practices.
  • The collaboration is expected to expand national availability, accelerate product adoption, & enhance purchasing efficiency for non-pharmaceutical regenerative solutions.
  • PetVivo holds twelve patents & six trade secrets protecting its biomaterials & production processes.
  • Forward-looking statements regarding development & commercial timelines are included in the announcement with associated risks outlined in the company's SEC filings.